Diversify Advisory Services LLC Has $1.80 Million Stock Position in Edwards Lifesciences Corporation (NYSE:EW)

Diversify Advisory Services LLC increased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 24.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,651 shares of the medical research company's stock after buying an additional 4,650 shares during the quarter. Diversify Advisory Services LLC's holdings in Edwards Lifesciences were worth $1,804,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. Global X Japan Co. Ltd. raised its position in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the sale, the chief financial officer directly owned 41,098 shares of the company's stock, valued at $3,057,691.20. This represents a 21.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daveen Chopra sold 1,500 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president directly owned 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,848 shares of company stock valued at $2,314,488. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Piper Sandler raised their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Finally, Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of "Hold" and a consensus target price of $81.00.

Edwards Lifesciences Stock Up 0.3%

Shares of EW stock traded up $0.26 on Friday, hitting $76.44. The company's stock had a trading volume of 4,816,601 shares, compared to its average volume of 5,284,402. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. Edwards Lifesciences Corporation has a fifty-two week low of $58.93 and a fifty-two week high of $88.50. The firm's fifty day moving average price is $76.50 and its 200-day moving average price is $73.44. The stock has a market capitalization of $44.84 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.84 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.66 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.